QCG
VTVT icon

Quadrant Capital Group’s vTv Therapeutics VTVT Stock Holding History

Quadrant Capital Group’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-19
Closed -$3K – 2081
2016
Q1 		$3K Buy
+19
New +$4.73K ﹤0.01% 1311

Other funds holding VTVT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $102M AUM 0.13% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Quadrant Capital Group's VTVT Position: Q2 2016 in Review

Quadrant Capital Group sold out of vTv Therapeutics (VTVT) in Q2 2016, closing a stake of 19 shares — an estimated $3K sold.

Quadrant Capital Group first reported a position in VTVT in Q1 2016 and held it in 1 quarter. The position peaked at $3K in Q1 2016. 35 funds tracked by Wall St. Rank hold VTVT as of Q2 2016.

  • Quadrant Capital Group reported no remaining vTv Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Quadrant Capital Group sold 19 vTv Therapeutics shares in Q2 2016, an estimated $3K.
  • Quadrant Capital Group first reported a position in vTv Therapeutics in Q1 2016 and held it in 1 quarter.
  • Quadrant Capital Group's vTv Therapeutics position peaked at $3K in Q1 2016.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2016.

Based on Quadrant Capital Group's 13F filing for Q2 2016, filed 28 Jul 2016.